PDMS Microfluidic Chip for Multiplexed Testing of Antibiotics against Tuberculosis

• A. Torres-Simón ^[1] ; R. González del Río ^[3] ; A. Muñoz-Barrutia ^[2] ; J. J. Vaquero ^[2]
  1. [1] Universidad Carlos III de Madrid

     Universidad Carlos III de Madrid

     Madrid, España

     
  2. [2] Instituto de Investigación Sanitaria Gregorio Marañón

     Instituto de Investigación Sanitaria Gregorio Marañón

     Madrid, España

     
  3. [3] GlaxoSmithKline-Global Health R&D, Tres Cantos, Madrid, España,

  Mostrar afiliaciones +
• Localización: Libro de Actas del XXXVI Congreso Anual de la Sociedad Española de Ingeniería Biomédica / Ma Gloria Bueno García (dir.), 2018, ISBN 978-84-09-06253-9, págs. 279-282
• Idioma: español
• Texto completo no disponible (Saber más ...)
• Resumen

  • Tuberculosis (TB) is the ninth leading cause of death worldwide, killing an estimate of 1.6 million people per year [1]. In recent times, multidrug resistant tuberculosis has become a major global concern, evidencing the necessity of developing powerful drug combinationsfor an effective treatment of the disease. In this study, we present a multiplexed microfluidic platform that accelerates the testing of antibiotic combinations against tuberculosis, in an attempt to reduce the time invested in the preclinical phase of the drug discovery process. The developed device consists of a PDMS (Polydimethylsiloxane) chip composed of four microchannels of rectangular cross-section (240x300 μm) produced by soft lithography, and a 3-D printed structure that allows the microfluidic chip to be integrated into a microscope. The new microfluidic chip enables the simultaneous and independent testing of various antibiotics, reducing by a factor of four the testing time of current methods. Single-cell analysis of Mycobacterium tuberculosis expressing GFP can be realized in the microfluidic device, providing researchers with crucial information about phenotypic heterogeneity in bacterial strains. The results demonstrate the utility of the proposed lab-on-a-chip framework for the long-term monitoring of M. tuberculosis and the concurrent assessment of the susceptibility of mycobacterium to four different antibiotic cocktails by time-lapse fluorescence microscopy.